{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:49:13Z","timestamp":1790812153363,"version":"4.1.0"},"reference-count":100,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinology and Metabolism Clinics of North America"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.ecl.2022.02.010","type":"journal-article","created":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T07:37:11Z","timestamp":1656920231000},"page":"539-555","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"title":["Hypertriglyceridemia"],"prefix":"10.1016","volume":"51","author":[{"given":"Alan","family":"Chait","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ecl.2022.02.010_bib1","unstructured":"Feingold KR. Introduction to Lipids and Lipoproteins. In: Feingold KR, Anawalt B, Boyce A, et\u00a0al., eds. Endotext. South Dartmouth (MA)2000."},{"issue":"47","key":"10.1016\/j.ecl.2022.02.010_bib2","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1093\/eurheartj\/ehab551","article-title":"Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society","volume":"42","author":"Ginsberg","year":"2021","journal-title":"Eur Heart J"},{"issue":"Suppl","key":"10.1016\/j.ecl.2022.02.010_bib3","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1194\/jlr.R800030-JLR200","article-title":"GPIHBP1, a GPI-anchored protein required for the lipolytic processing of triglyceride-rich lipoproteins","volume":"50","author":"Beigneux","year":"2009","journal-title":"J\u00a0Lipid Res"},{"issue":"7","key":"10.1016\/j.ecl.2022.02.010_bib4","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.bbalip.2014.03.013","article-title":"Physiological regulation of lipoprotein lipase","volume":"1841","author":"Kersten","year":"2014","journal-title":"Biochim Biophys Acta"},{"issue":"5","key":"10.1016\/j.ecl.2022.02.010_bib5","first-page":"246","article-title":"[Identification of variants in LMF1 gene associated with primary hypertriglyceridemia]","volume":"27","author":"Lamiquiz-Moneo","year":"2015","journal-title":"Clin Investig Arterioscler"},{"issue":"1","key":"10.1016\/j.ecl.2022.02.010_bib6","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.atherosclerosis.2011.07.019","article-title":"Apolipoprotein A-V; a potent triglyceride reducer","volume":"219","author":"Nilsson","year":"2011","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.ecl.2022.02.010_bib7","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1161\/01.ATV.0000153087.36428.dd","article-title":"Inherited apolipoprotein A-V deficiency in severe hypertriglyceridemia","volume":"25","author":"Priore Oliva","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"8","key":"10.1016\/j.ecl.2022.02.010_bib8","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1172\/JCI86610","article-title":"ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors","volume":"126","author":"Gordts","year":"2016","journal-title":"J\u00a0Clin Invest"},{"issue":"9","key":"10.1016\/j.ecl.2022.02.010_bib9","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1161\/ATVBAHA.113.301637","article-title":"Hepatic remnant lipoprotein clearance by heparan sulfate proteoglycans and low-density lipoprotein receptors depend on dietary conditions in mice","volume":"33","author":"Foley","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ecl.2022.02.010_bib10","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1172\/JCI107334","article-title":"Evidence for a common saturable triglyceride removal mechanism for chylomicrons and very low density lipoproteins in man","volume":"52","author":"Brunzell","year":"1973","journal-title":"J\u00a0Clin Invest"},{"issue":"12","key":"10.1016\/j.ecl.2022.02.010_bib11","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaa674","article-title":"Lipid management in patients with endocrine disorders: an endocrine society clinical practice guideline","volume":"105","author":"Newman","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2022.02.010_bib12","unstructured":"Chait A, Subramanian S. Hypertriglyceridemia: pathophysiology, role of genetics, consequences, and treatment. In: Feingold KR, Anawalt B, Boyce A, et\u00a0al., eds. Endotext. South Dartmouth (MA)2000."},{"key":"10.1016\/j.ecl.2022.02.010_bib13","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1172\/JCI107332","article-title":"Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia","volume":"52","author":"Goldstein","year":"1973","journal-title":"J\u00a0Clin Invest"},{"issue":"7810","key":"10.1016\/j.ecl.2022.02.010_bib14","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/S0140-6736(73)91598-5","article-title":"Family study of serum lipids and lipoproteins in coronary heart-disease","volume":"1","author":"Nikkila","year":"1973","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.ecl.2022.02.010_bib15","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1038\/ng.2797","article-title":"Discovery and refinement of loci associated with lipid levels","volume":"45","author":"Willer","year":"2013","journal-title":"Nat Genet"},{"issue":"5","key":"10.1016\/j.ecl.2022.02.010_bib16","doi-asserted-by":"crossref","first-page":"e1006078","DOI":"10.1371\/journal.pgen.1006078","article-title":"The contribution of GWAS loci in familial dyslipidemias","volume":"12","author":"Ripatti","year":"2016","journal-title":"PLoS Genet"},{"issue":"9","key":"10.1016\/j.ecl.2022.02.010_bib17","doi-asserted-by":"crossref","first-page":"31A","DOI":"10.1210\/jcem.97.9.zeg31a","article-title":"Patient information page from the hormone foundations. patient guide to the assessment and treatment of hypertriglyceridemia (high triglycerides)","volume":"97","author":"Berglund","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.ecl.2022.02.010_bib18","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S2213-8587(13)70191-8","article-title":"The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management","volume":"2","author":"Hegele","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"10.1016\/j.ecl.2022.02.010_bib19","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s40291-019-00412-2","article-title":"The gene score for predicting hypertriglyceridemia: new insights from a czech case-control study","volume":"23","author":"Hubacek","year":"2019","journal-title":"Mol Diagn Ther"},{"issue":"8","key":"10.1016\/j.ecl.2022.02.010_bib20","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11883-021-00939-y","article-title":"The genetic basis of hypertriglyceridemia","volume":"23","author":"Carrasquilla","year":"2021","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.ecl.2022.02.010_bib21","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3389\/fendo.2020.00455","article-title":"Genetics of hypertriglyceridemia","volume":"11","author":"Dron","year":"2020","journal-title":"Front Endocrinol"},{"issue":"24","key":"10.1016\/j.ecl.2022.02.010_bib22","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1161\/01.CIR.0000130646.93255.86","article-title":"Nomogram to diagnose familial combined hyperlipidemia on the basis of results of a 5-year follow-up study","volume":"109","author":"Veerkamp","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.ecl.2022.02.010_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2018.11.013","article-title":"Incidence of cardiovascular disease in familial combined hyperlipidemia: a 15-year follow-up study","volume":"280","author":"Luijten","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ecl.2022.02.010_bib24","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1161\/01.ATV.13.7.1110","article-title":"Stable isotopes show a direct relation between VLDL apoB overproduction and serum triglyceride levels and indicate a metabolically and biochemically coherent basis for familial combined hyperlipidemia","volume":"13","author":"Venkatesan","year":"1993","journal-title":"Arterioscler Thromb"},{"issue":"9","key":"10.1016\/j.ecl.2022.02.010_bib25","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1194\/jlr.R200004-JLR200","article-title":"Metabolic origins and clinical significance of LDL heterogeneity","volume":"43","author":"Berneis","year":"2002","journal-title":"J\u00a0Lipid Res"},{"issue":"4","key":"10.1016\/j.ecl.2022.02.010_bib26","doi-asserted-by":"crossref","first-page":"508","DOI":"10.2337\/dbi19-0007","article-title":"Remnants of the triglyceride-rich lipoproteins, diabetes, and cardiovascular disease","volume":"69","author":"Chait","year":"2020","journal-title":"Diabetes"},{"issue":"8","key":"10.1016\/j.ecl.2022.02.010_bib27","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1161\/ATVBAHA.111.226365","article-title":"An increased burden of common and rare lipid-associated risk alleles contributes to the phenotypic spectrum of hypertriglyceridemia","volume":"31","author":"Johansen","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"8023","key":"10.1016\/j.ecl.2022.02.010_bib28","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1016\/S0140-6736(77)92717-9","article-title":"Type-III Hyperlipoproteinaemia (\"remnant removal disease\"). Insight into the pathogenetic mechanism","volume":"1","author":"Chait","year":"1977","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.ecl.2022.02.010_bib29","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","volume":"120","author":"Alberti","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.ecl.2022.02.010_bib30","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1161\/01.CIR.102.2.179","article-title":"Hypertriglyceridemic waist : a marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein b; small, dense LDL) in men?","volume":"102","author":"Lemieux","year":"2000","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.ecl.2022.02.010_bib31","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.2337\/dc19-0501","article-title":"Residual hypertriglyceridemia and estimated atherosclerotic cardiovascular disease risk by statin use in U.S. adults with diabetes: national health and nutrition examination survey 2007-2014","volume":"42","author":"Fan","year":"2019","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.ecl.2022.02.010_bib32","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1001\/jama.280.2.140","article-title":"Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes Control and Complications Trial","volume":"280","author":"Purnell","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.ecl.2022.02.010_bib33","first-page":"180A","article-title":"Weight gain accompanying intensive diabetes therapy in type 1 diabetes is associated with higher levels of dense LDL cholesterol","volume":"44","author":"Purnell","year":"1996","journal-title":"J\u00a0Investig Med"},{"key":"10.1016\/j.ecl.2022.02.010_bib34","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJM196701192760305","article-title":"Fat transport and lipoproteins - an integrated approach to mechanisms and disorders","volume":"276","author":"Fredrickson","year":"1967","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ecl.2022.02.010_bib35","series-title":"Lipoprotein deficiency syndromes","first-page":"227","article-title":"Primary lipoprotein lipase deficiency","author":"Brunzell","year":"1986"},{"key":"10.1016\/j.ecl.2022.02.010_bib36","series-title":"Familial lipoprotein lipase deficiency, apo CII deficiency and hepatic lipase deficiency. The metabolic and molecular basis of inherited disease","first-page":"2789","author":"Brunzell","year":"2001"},{"issue":"3","key":"10.1016\/j.ecl.2022.02.010_bib37","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1139\/Y09-005","article-title":"Novel LPL mutations associated with lipoprotein lipase deficiency: two case reports and a literature review","volume":"87","author":"Rahalkar","year":"2009","journal-title":"Can J Physiol Pharmacol"},{"issue":"3","key":"10.1016\/j.ecl.2022.02.010_bib38","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/907","article-title":"DNA sequence diversity in a 9.7-kb region of the human lipoprotein lipase gene","volume":"19","author":"Nickerson","year":"1998","journal-title":"Nat Genet"},{"issue":"2","key":"10.1016\/j.ecl.2022.02.010_bib39","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1365-2796.2012.02516.x","article-title":"Mutations in LPL, APOC2, APOA5, GPIHBP1 and LMF1 in patients with severe hypertriglyceridaemia","volume":"272","author":"Surendran","year":"2012","journal-title":"J\u00a0Intern Med"},{"issue":"6","key":"10.1016\/j.ecl.2022.02.010_bib40","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/j.1365-2796.1992.tb01256.x","article-title":"Hypertriglyceridaemia due to genetic defects in lipoprotein lipase and apolipoprotein C-II","volume":"231","author":"Fojo","year":"1992","journal-title":"J\u00a0Intern Med"},{"issue":"2","key":"10.1016\/j.ecl.2022.02.010_bib41","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/01.mol.0000217892.00618.54","article-title":"APOA5 and triglyceride metabolism, lesson from human APOA5 deficiency","volume":"17","author":"Calandra","year":"2006","journal-title":"Curr Opin Lipidol"},{"issue":"6","key":"10.1016\/j.ecl.2022.02.010_bib42","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nrendo.2015.26","article-title":"Chylomicronaemia-current diagnosis and future therapies","volume":"11","author":"Brahm","year":"2015","journal-title":"Nat Rev Endocrinol"},{"issue":"3","key":"10.1016\/j.ecl.2022.02.010_bib43","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s10545-011-9406-5","article-title":"Deletion of GPIHBP1 causing severe chylomicronemia","volume":"35","author":"Rios","year":"2012","journal-title":"J\u00a0Inherit Metab Dis"},{"issue":"9","key":"10.1016\/j.ecl.2022.02.010_bib44","doi-asserted-by":"crossref","first-page":"626","DOI":"10.7326\/M19-0203","article-title":"The chylomicronemia syndrome is most often multifactorial: a narrative review of causes and treatment","volume":"170","author":"Chait","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ecl.2022.02.010_bib45","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0026-0495(83)90184-1","article-title":"Severe hypertriglyceridemia: role of familial and acquired disorders","volume":"32","author":"Chait","year":"1983","journal-title":"Metabolism"},{"issue":"11","key":"10.1016\/j.ecl.2022.02.010_bib46","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1210\/jc.2011-1159","article-title":"Clinical review#: Lipodystrophies: genetic and acquired body fat disorders","volume":"96","author":"Garg","year":"2011","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.ecl.2022.02.010_bib47","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.2337\/diacare.26.6.1819","article-title":"Kobberling type of familial partial lipodystrophy: an underrecognized syndrome","volume":"26","author":"Herbst","year":"2003","journal-title":"Diabetes Care"},{"issue":"20","key":"10.1016\/j.ecl.2022.02.010_bib48","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1161\/CIR.0b013e3182160726","article-title":"Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association","volume":"123","author":"Miller","year":"2011","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.ecl.2022.02.010_bib49","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/0002-8703(86)90296-6","article-title":"The triglyceride issue: a view from framingham","volume":"112","author":"Castelli","year":"1986","journal-title":"Am Heart J"},{"issue":"3","key":"10.1016\/j.ecl.2022.02.010_bib50","doi-asserted-by":"crossref","first-page":"216","DOI":"10.2174\/157340309788970315","article-title":"Triglycerides and cardiovascular risk","volume":"5","author":"Harchaoui","year":"2009","journal-title":"Curr Cardiol Rev"},{"issue":"1","key":"10.1016\/j.ecl.2022.02.010_bib51","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1365-2796.2010.02333.x","article-title":"Nonfasting cholesterol and triglycerides and association with risk of myocardial infarction and total mortality: the Copenhagen City Heart Study with 31 years of follow-up","volume":"270","author":"Langsted","year":"2011","journal-title":"J\u00a0Intern Med"},{"issue":"9943","key":"10.1016\/j.ecl.2022.02.010_bib52","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S0140-6736(14)61177-6","article-title":"Triglycerides and cardiovascular disease","volume":"384","author":"Nordestgaard","year":"2014","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ecl.2022.02.010_bib53","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/00043798-199604000-00014","article-title":"Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta- analysis of population-based prospective studies","volume":"3","author":"Hokanson","year":"1996","journal-title":"J\u00a0Cardiovasc Risk"},{"issue":"11","key":"10.1016\/j.ecl.2022.02.010_bib54","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1161\/ATVBAHA.109.201020","article-title":"Genetic variants influencing circulating lipid levels and risk of coronary artery disease","volume":"30","author":"Waterworth","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"7307","key":"10.1016\/j.ecl.2022.02.010_bib55","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/nature09270","article-title":"Biological, clinical and population relevance of 95 loci for blood lipids","volume":"466","author":"Teslovich","year":"2010","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.ecl.2022.02.010_bib56","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1161\/01.ATV.0000219283.10832.43","article-title":"Lipoprotein lipase S447X: a naturally occurring gain-of-function mutation","volume":"26","author":"Rip","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"11","key":"10.1016\/j.ecl.2022.02.010_bib57","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/ng.2795","article-title":"Common variants associated with plasma triglycerides and risk for coronary artery disease","volume":"45","author":"Do","year":"2013","journal-title":"Nat Genet"},{"issue":"9","key":"10.1016\/j.ecl.2022.02.010_bib58","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1001\/jama.2017.0972","article-title":"Association of rare and common variation in the lipoprotein lipase gene with coronary artery disease","volume":"317","author":"Khera","year":"2017","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.ecl.2022.02.010_bib59","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1307095","article-title":"Loss-of-function mutations in APOC3, triglycerides, and coronary disease","volume":"371","author":"Blood","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.ecl.2022.02.010_bib60","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1308027","article-title":"Loss-of-function mutations in APOC3 and risk of ischemic vascular disease","volume":"371","author":"Jorgensen","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.ecl.2022.02.010_bib61","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1056\/NEJMoa1510926","article-title":"Inactivating variants in ANGPTL4 and risk of coronary artery disease","volume":"374","author":"Dewey","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.ecl.2022.02.010_bib62","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1056\/NEJMoa1507652","article-title":"Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease","volume":"374","author":"Myocardial Infarction","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.ecl.2022.02.010_bib63","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.2310\/JIM.0b013e3182686918","article-title":"Mutation screening of the APOA5 gene in subjects with coronary artery disease","volume":"60","author":"Soufi","year":"2012","journal-title":"J\u00a0Investig Med"},{"issue":"7537","key":"10.1016\/j.ecl.2022.02.010_bib64","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/nature13917","article-title":"Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction","volume":"518","author":"Do","year":"2015","journal-title":"Nature"},{"issue":"16","key":"10.1016\/j.ecl.2022.02.010_bib65","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1016\/j.jacc.2017.02.030","article-title":"ANGPTL3 deficiency and protection against coronary artery disease","volume":"69","author":"Stitziel","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.ecl.2022.02.010_bib66","doi-asserted-by":"crossref","first-page":"e003434","DOI":"10.1161\/JAHA.112.003434","article-title":"Arterial retention of remnant lipoproteins ex\u00a0vivo is increased in insulin resistance because of increased arterial biglycan and production of cholesterol-rich atherogenic particles that can be improved by ezetimibe in the JCR:LA-cp rat","volume":"1","author":"Mangat","year":"2012","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"1","key":"10.1016\/j.ecl.2022.02.010_bib67","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1093\/clinchem\/41.1.153","article-title":"Atherogenic nature of triglycerides, postprandial lipidemia, and triglyceride-rich remnant lipoproteins","volume":"41","author":"Zilversmit","year":"1995","journal-title":"Clin Chem"},{"key":"10.1016\/j.ecl.2022.02.010_bib68","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nature00804","article-title":"Subendothelial retention of atherogenic lipoproteins in early atherosclerosis","volume":"417","author":"Skalen","year":"2002","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.ecl.2022.02.010_bib69","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1161\/01.ATV.15.4.534","article-title":"Selective retention of VLDL, IDL, and LDL in the arterial intima of genetically hyperlipidemic rabbits in\u00a0vivo. Molecular size as a determinant of fractional loss from the intima-inner media","volume":"15","author":"Nordestgaard","year":"1995","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"8","key":"10.1016\/j.ecl.2022.02.010_bib70","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1161\/ATVBAHA.111.226100","article-title":"Triglycerides and heart disease: still a hypothesis?","volume":"31","author":"Goldberg","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"12","key":"10.1016\/j.ecl.2022.02.010_bib71","doi-asserted-by":"crossref","DOI":"10.1172\/JCI145800","article-title":"Eruptive xanthoma model reveals endothelial cells internalize and metabolize chylomicrons, leading to extravascular triglyceride accumulation","volume":"131","author":"Cabodevilla","year":"2021","journal-title":"J\u00a0Clin Invest"},{"issue":"11","key":"10.1016\/j.ecl.2022.02.010_bib72","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.3109\/00365521.2011.605464","article-title":"Time trends in incidence, etiology, and case fatality rate of the first attack of acute pancreatitis","volume":"46","author":"Omdal","year":"2011","journal-title":"Scand J Gastroenterol"},{"issue":"2","key":"10.1016\/j.ecl.2022.02.010_bib73","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s11894-009-0016-4","article-title":"The changing character of acute pancreatitis: epidemiology, etiology, and prognosis","volume":"11","author":"Lowenfels","year":"2009","journal-title":"Curr Gastroenterol Rep"},{"issue":"1","key":"10.1016\/j.ecl.2022.02.010_bib74","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1748-1716.2008.01933.x","article-title":"The role of free fatty acids, pancreatic lipase and Ca+ signalling in injury of isolated acinar cells and pancreatitis model in lipoprotein lipase-deficient mice","volume":"195","author":"Yang","year":"2009","journal-title":"Acta Physiol (Oxf)"},{"issue":"8","key":"10.1016\/j.ecl.2022.02.010_bib75","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.ejim.2014.08.008","article-title":"Current knowledge of hypertriglyceridemic pancreatitis","volume":"25","author":"Valdivielso","year":"2014","journal-title":"Eur J Intern Med"},{"issue":"7","key":"10.1016\/j.ecl.2022.02.010_bib76","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1097\/MCG.0000000000000846","article-title":"Elevated serum triglycerides in the prognostic assessment of acute pancreatitis: a systematic review and meta-analysis of observational studies","volume":"51","author":"Wang","year":"2017","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1016\/j.ecl.2022.02.010_bib77","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2337\/diacare.4.3.343","article-title":"Chylomicronemia syndrome in diabetes mellitus","volume":"4","author":"Chait","year":"1981","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.ecl.2022.02.010_bib78","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1056\/NEJM199609193351203","article-title":"Premature atherosclerosis in patients with familial chylomicronemia caused by mutations in the lipoprotein lipase gene","volume":"335","author":"Benlian","year":"1996","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.ecl.2022.02.010_bib79","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1046\/j.1365-2362.2003.01129.x","article-title":"Novel LPL mutation (L303F) found in a patient associated with coronary artery disease and severe systemic atherosclerosis","volume":"33","author":"Saika","year":"2003","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.ecl.2022.02.010_bib80","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.20150.1","article-title":"Recent advances in understanding lipodystrophy: a focus on lipodystrophy-associated cardiovascular disease and potential effects of leptin therapy on cardiovascular function","volume":"8","author":"Bruder-Nascimento","year":"2019","journal-title":"F1000Res"},{"issue":"2","key":"10.1016\/j.ecl.2022.02.010_bib81","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.pathol.2018.11.004","article-title":"Lipodystrophies, dyslipidaemias and atherosclerotic cardiovascular disease","volume":"51","author":"Hussain","year":"2019","journal-title":"Pathology"},{"issue":"16","key":"10.1016\/j.ecl.2022.02.010_bib82","doi-asserted-by":"crossref","first-page":"42H","DOI":"10.1016\/0002-9149(89)90115-X","article-title":"Relation between baseline lipid and lipoprotein values and the incidence of coronary heart disease in the Helsinki Heart Study","volume":"63","author":"Manninen","year":"1989","journal-title":"Am J Cardiol"},{"issue":"6","key":"10.1016\/j.ecl.2022.02.010_bib83","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJM199908053410604","article-title":"Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. veterans affairs high-density lipoprotein cholesterol intervention trial study group","volume":"341","author":"Rubins","year":"1999","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.ecl.2022.02.010_bib84","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.jacl.2016.03.008","article-title":"Triglyceride-lowering therapies reduce cardiovascular disease event risk in subjects with hypertriglyceridemia","volume":"10","author":"Maki","year":"2016","journal-title":"J\u00a0Clin Lipidol"},{"issue":"4","key":"10.1016\/j.ecl.2022.02.010_bib85","doi-asserted-by":"crossref","first-page":"771","DOI":"10.2337\/db19-0973","article-title":"PPARA polymorphism influences the cardiovascular benefit of fenofibrate in type 2 diabetes: findings from ACCORD-lipid","volume":"69","author":"Morieri","year":"2020","journal-title":"Diabetes"},{"key":"10.1016\/j.ecl.2022.02.010_bib86","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ahj.2018.09.011","article-title":"Rationale and design of the pemafibrate to reduce cardiovascular outcomes by reducing triglycerides in patients with diabetes (PROMINENT) study","volume":"206","author":"Pradhan","year":"2018","journal-title":"Am Heart J"},{"issue":"19","key":"10.1016\/j.ecl.2022.02.010_bib87","doi-asserted-by":"crossref","first-page":"e013543","DOI":"10.1161\/JAHA.119.013543","article-title":"Marine omega-3 supplementation and cardiovascular disease: an updated meta-analysis of 13 randomized controlled trials involving 127 477 participants","volume":"8","author":"Hu","year":"2019","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"1","key":"10.1016\/j.ecl.2022.02.010_bib88","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"9567","key":"10.1016\/j.ecl.2022.02.010_bib89","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(07)60527-3","article-title":"Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis","volume":"369","author":"Yokoyama","year":"2007","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.ecl.2022.02.010_bib90","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1001\/jama.2020.22258","article-title":"Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the strength randomized clinical trial","volume":"324","author":"Nicholls","year":"2020","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.ecl.2022.02.010_bib91","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1161\/ATVBAHA.119.313286","article-title":"Emerging mechanisms of cardiovascular protection for the Omega-3 fatty acid eicosapentaenoic acid","volume":"40","author":"Mason","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"13","key":"10.1016\/j.ecl.2022.02.010_bib92","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.2174\/0929867324666170609081612","article-title":"APOC-III antisense oligonucleotides: a new option for the treatment of hypertriglyceridemia","volume":"25","author":"Schmitz","year":"2018","journal-title":"Curr Med Chem"},{"issue":"5","key":"10.1016\/j.ecl.2022.02.010_bib93","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1400283","article-title":"Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia","volume":"373","author":"Gaudet","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.ecl.2022.02.010_bib94","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1701329","article-title":"Cardiovascular and metabolic effects of ANGPTL3 antisense oligonucleotides","volume":"377","author":"Graham","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.ecl.2022.02.010_bib95","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.jacl.2012.08.002","article-title":"Severe hypertriglyceridemia","volume":"6","author":"Brown","year":"2012","journal-title":"J\u00a0Clin Lipidol"},{"issue":"6","key":"10.1016\/j.ecl.2022.02.010_bib96","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1080\/17512433.2018.1480368","article-title":"Pharmacological treatment options for severe hypertriglyceridemia and familial chylomicronemia syndrome","volume":"11","author":"Chaudhry","year":"2018","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.ecl.2022.02.010_bib97","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s11892-006-0040-9","article-title":"Treatment of hypertriglyceridemia","volume":"6","author":"Capell","year":"2006","journal-title":"Curr Diab Rep"},{"issue":"23","key":"10.1016\/j.ecl.2022.02.010_bib98","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1056\/NEJMoa1400284","article-title":"Targeting APOC3 in the familial chylomicronemia syndrome","volume":"371","author":"Gaudet","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.ecl.2022.02.010_bib99","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa1715944","article-title":"Volanesorsen and triglyceride levels in familial chylomicronemia syndrome","volume":"381","author":"Witztum","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.ecl.2022.02.010_bib100","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1210\/jc.2014-4491","article-title":"Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin","volume":"100","author":"Diker-Cohen","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"}],"container-title":["Endocrinology and Metabolism Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852922000251?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852922000251?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:47:08Z","timestamp":1760176028000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889852922000251"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":100,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S0889852922000251"],"URL":"https:\/\/doi.org\/10.1016\/j.ecl.2022.02.010","relation":{},"ISSN":["0889-8529"],"issn-type":[{"value":"0889-8529","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hypertriglyceridemia","name":"articletitle","label":"Article Title"},{"value":"Endocrinology and Metabolism Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ecl.2022.02.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}